Happy to share this large collaborative work in its final form : Liso-cel vs Axi-cel — similar efficacy with less toxicity.

doi.org/10.1182/bloo...

#lymsm #CARTCell

🌴#Tandem25, Thursday @ 6:45pm🍍
Hyperferritinemia syndromes following CD19 CAR T cells for Lymphoma
- Hyperferritinemia (HF) = inferior survival.
- HF = greater toxicity.
- HLH-like manifestations in 28% of patients.
- Impact of HF independent of CRS, ICANS, and tumor burden.
#lymsm, #CARTCell

🩸#ASH24 Sunday @ 6pm🩸
Real-world comparison of CD19 CAR T cells for LBCL.
- 501 patients from 4 centers.
- Inferior outcomes with tisa-cel.
- Higher ORR and CR rates with liso-cel.
- Liso-cel and axi-cel = similar PFS and OS rates.
- Less toxicities with liso-cell.
#lymsm, #CARTCell

🩸#ASH24 Sunday @ 12:15pm🩸
Point-of-care vs commercial CD19 CAR-T therapies.
- Median vein-to-vein time: POC=11d, axi-cel=38d, tisa-cel=44d.
- Grade 2+ CRS: POC=26%, axi-cel=52%, tisa-cel=37%.
- Comparable survival outcomes.
#lymsm, #CARTCell

! Hot off the press !
Excited to share this interesting case of long-term axi-cel persistence and to brainstorm about the role of immune checkpoint inhibitors in CAR T-cell therapies.
doi.org/10.1080/1042...

#lymphoidneoplasia, #CART, #Immunotherapy

I am happy to share our new article in
@BloodJournal
. Acute myelopathy is a rare but devastating complication of CAR T-cell therapy: authors.elsevier.com/a/1k5wW1UYwn...

#CART #CellTherapy #Lymphoma #All